Polyrizon Ltd (PLRZ)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)
NEW YORK, NY / ACCESSWIRE / October 30, 2024 / Aegis Capital Corp. acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ:PLRZ).
Polyrizon Ltd (PLRZ) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Polyrizon Ltd ever had a stock split?
Polyrizon Ltd Profile
| Biotechnology Industry | Healthcare Sector | Tomer Izraeli CEO | NASDAQ (CM) Exchange | M79549123 CUSIP |
| IL Country | 2 Employees | - Last Dividend | 28 Nov 2025 Last Split | - IPO Date |
Overview
Polyrizon Ltd. is a biotech company based in Israel, focusing on the innovative development of medical device hydrogels, particularly in the form of nasal sprays. Founded in 2005 and headquartered in Ra'anana, Israel, Polyrizon is dedicated to creating solutions that offer protection against viruses and allergens by preventing them from making contact with nasal epithelial tissue. This groundbreaking approach aims to elevate the standard of respiratory health and offer a non-pharmacological defense against common and emergent respiratory threats.
Products and Services
- PL-14 (Nasal Allergies Blocker)
PL-14 is a specialized nasal spray developed by Polyrizon to combat nasal allergies. By forming a protective barrier in the nasal pathways, it prevents allergens from triggering allergic reactions, providing relief from common symptoms such as sneezing, nasal congestion, and itching. This product represents a novel approach to allergy management, focusing on prevention rather than just symptom control.
- PL-15 (For COVID-19)
The PL-15 nasal spray is a response to the global COVID-19 pandemic, designed to offer an added layer of defense against the SARS-CoV-2 virus. This product employs Polyrizon’s unique hydrogel technology to create a barrier that can reduce the virus's ability to attach to nasal epithelial cells, thereby helping to lower the risk of infection and spread of the virus. It's a pioneering tool in the fight against COVID-19, offering a new way to protect individuals in combination with existing health measures.
- PL-16 (For Influenza)
PL-16 targets the influenza virus, providing a protective hydrogel barrier in the nasal passages to inhibit the virus's access to nasal cells. Similar to its counterparts, it leverages Polyrizon’s hydrogel technology to block the entry of the virus, acting as a preventative measure during flu season. This product underscores Polyrizon’s commitment to expanding its range of respiratory health solutions, addressing not only everyday health concerns but also seasonal outbreaks.
